Ryan H. Moy, MD, PhD

Ryan H. Moy, MD, PhD, is the principal investigator of a phase 2 trial evaluating defactinib plus avutometinib in patients with diffuse gastric/GEJ carcinoma.

Ryan H. Moy, MD, PhD, noted that patients with early-onset esophagogastric cancer tend to have more advanced disease.